medigraphic.com
ISSN 0188-9796 (Print)

2006, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2006; 14 (3)

Metabolic and hormonal conditions in menopause

Morato HL, Malacara HJM

Language: Spanish
References: 112
Page: 149-155
PDF size: 85.90 Kb.


Text Extraction

No abstract


REFERENCES

  1. Wise PM, Smith MJ, Dubal DB. Neuroendocrine influences and repercussions of the menopause. Endoc Rev 1999; 20: 243-8.

  2. Velasco E, Malacara JM, Cervantes F, Díaz de León J, Dávalos G, Castillo J. Gonadotropins and prolactin serum levels during the perimenopausal period: Correlation with diverse factors. Fertil Steril 1990; 53: 56-60.

  3. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal Transition: a cross-sectional study of a population-based sample. J Clin Endoc Metab 1995; 80: 3537-45.

  4. Labrie F, Luu.The V, Labrie C. Endocrine and Intracrine Sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepinandroesterone. Endoc Rev 2003; 24: 152-182.

  5. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14: 245-255.

  6. van Zonneveld P, Scheffer GJ. Hormones and reproductive ageing. Maturitas 2001; 38: 83-94.

  7. Morato HL. Cambios endocrinos en la perimenopausia y la postmenopausia. En: S. Carranza-Lira: Atención Integral del Climaterio. Ed. Masson-Doyma, México, 2002: 25-37.

  8. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14: 245-255.

  9. Buckler HM, Evans CA, Mamtora H. Gonadotropin, steroid, and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory rebound cycles. J Clin

  10. Endocrinol Metab 1991; 72: 116-24.

  11. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate JH, exhaustion. J Clin Endocrinol Metab 1987; 65: 1231-6.

  12. Huerta R, Malacara JM, Fajardo ME, Nava LE, Bocanegra A, Sánchez J. High frequency FSH and LH pulses in obese menopausal women. Endocrine 1997; 7: 281-286.

  13. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol and progesterone concentrations during the menstrual cycle of older women. J Clin Endoc Metab 1976; 42: 629-36.

  14. Burger HG, Dudley EC, Hopper JL. Prospectively measured levels of serum follicle-stimulating hormone, estradiol and the dimeric inhibins during the menopausal transition in population-based cohort of women. J Clin Endoc Metab 1999; 84: 4025- 30.

  15. Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998; 19: 397-428.

  16. Santoro N, Brown JR, Adel T. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81: 1495- 501.

  17. Bancroft J, Cawood EH. Androgens and the menopause: a study of 40-60 year old women. Clin Endoc (Oxf) 1996; 45: 577-87.

  18. Arlt W, Justl HG, Callies F. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998; 83: 1928-1934.

  19. Labrie F, Luu-The V, Labrie C. Endocrine and Intracrine Sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandroesterone. Endocr Rev 2003; 24: 152-182.

  20. Arlt W. Androgen Therapy in women. Eur J Endocrinol 2006; 154: 1-11.

  21. Arlt W, Callies F, van Vlijmen JC. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013-1020.

  22. Kawano H, Yasue H, Kitagawa A. Dehydroepiandrosterone supplementation improves endotelial function and insulin sensitivity in men. J Clin Endoc Metab 2003; 88: 3190-3195.

  23. Kimonides VG, Khatibi NH, Svendsen CN. Dehydroepiandrosterone (DHEA) and DHEA-S protect Hyppocampal neurons against excitatory amino-acid induced neurotoxicity. Proc Natl Acad Sci 1998; 85: 1842-1867.

  24. Lovas K, Gebre-Medhin G, Trovik TS. Effect of DHEA on abdominal fat and insulin action in eldery women and men. A randomized study Controlled trial. JAMA 2004; 292: 2243-2248.

  25. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-376.

  26. Bachmann G, Bancroft J, Braunstein G. Female androgen insufficiency: The Princeton Consensus Statement on definition, classification and assessment. Fertil Steril 2002: 77: 660-665.

  27. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-29.

  28. Judd HL, Lucas WE, Judd GE. Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39: 1020-1024.

  29. Urban RJ. Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 1992; 21: 921-31.

  30. Katznelson L, Riskind PN, Saxe VC. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrin Metab 1998; 83: 761-764.

  31. Valles V. Factores de Riesgo cardiovascular en mujeres postmenopáusicas. Encuesta Nacional de Enfermedades Crónicas. Rev Inst Nal Nutr Salvador Zubirán 1994; 5: 20.

  32. Lozano-Ascencio R, Escamilla JA, Escobedo de la Peña J, López-Cervantes M. Tendencia de la mortalidad por cardiopatía isquémica en México, de 1950 a 1985. Salud Pública Mex 1990; 32: 406.

  33. Carr MC. The Emergence of the Metabolic Syndrome with Menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.

  34. Lerman GI, Aguilar-Salinas CA, Gómez-Pérez FJ. El síndrome metabólico. Posición de la Sociedad Mexicana de Nutrición y Endocrinología, sobre la definicion, fisiopatología y diagnóstico. Características del síndrome Metabólico en México. Rev Endoc Nutr 2004; 12: 109-122.

  35. Posadas RC, Yamamoto KL, Tapia CR. Epidemiología de las dislipidemias en México. En: C. Posadas R: Dislipidemias y Aterosclerosis, Edit. Interamericana, 1995: 117.

  36. Valles V. Factores de riesgo cardiovascular en mujeres postmenopáusicas. Encuesta Nacional de Enfermedades Crónicas. Rev Inst Nal Nutr Salvador Zubirán 1994; 5: 20.

  37. Morato HL, Lerman GI. Dislipidemias en el climaterio femenino y en ancianos. En: C. Posadas R. Dislipidemias y Aterosclerosis. Ed. Interamericana, 1995: 159-170.

  38. Morato HL. Dislipidemias. Alteraciones de la coagulación. En: JM Septién G. Climaterio: Estudio, diagnóstico y tratamiento. Edit. Intersistemas México, pp.: 106-112.

  39. Posadas CR, Brito ZO. Alteraciones metabólicas en el climaterio. En: S. Carranza-Lira: Atención Integral del Climaterio, Ed. Masson Doyma México, 2002: 101-115.

  40. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endoc Metab 1991; 73: 925-31.

  41. La Rosa JC. Metabolic effects of estrogens and progestins. Fert Ster 1994; 62 (suppl 2): S140.

  42. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) Trial. JAMA 1995; 273: 199-204.

  43. Mosca L. Estrógenos y aterosclerosis. Aterosclerosis 1999; 2(1).

  44. Grobbee DE. LIFT study to continue as planned. BMJ 2005; 331: 843.

  45. Saitta A, Altavilla D, Cucinotta D. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on NO concentrations, enothelin 1 levels and endothelium dependent vasodilation in postmenopausal women. Arterioescl Throm Vasc Biol 2001; 21: 1512-5.

  46. Lip GYH, Blann AD, Jones AF. Effects of HRT on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause. Am H J 1997; 134: 764.

  47. Tonstad S, Ose L, Gorberts C. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women. J Int Med 1995; 238: 39.

  48. Kats RJ, Hsia J, Walker P. Effects of hormonal replacement therapy on the circadian pattern of atherotrombotic risk factors. Am J Cardiol 1996; 78: 876.

  49. Hernández JS, Rodríguez CS, Pérez E. Tratamiento de las alteraciones metabólicas durante el climaterio. En: S. Carranza-Lira: Atención Integral del Climaterio. Ed. Masson- Doyma, México, 2002: 223-247.

  50. Gaspard UJ, Gottal JM, van den Brele FA. Postmenopausal changes of lipid and glucose metabolism; a review of their main aspects. Maturitas 1995; 21: 171-178.

  51. Hernández-Ono A, Monter-Carreola G, Zamora González J. Association of visceral fat with coronary risk factors in a population-based sample of postmenopausal women. Int

  52. J Obes 2002; 26: 33-9.

  53. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  54. Arriero PJ, Goran MI, Poehlman ET. Resting metabolic rate is lower in females compared to males. J Appl Physiol 1993; 75: 2514-2520.

  55. Guo SS, Zeller C, Cameron CW. Aging, body composition and lifestyle: The Fels Longitudinal Study. Am J Clin Nutr 1999; 70: 405-411.

  56. Crawford SL, Casey VA, Avis NE. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women´s Health Study. Menopause 2000; 7: 96-104.

  57. Crawford SL, Casey VA, Avis NE. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women´s Health Study. Menopause 2000; 7: 96-104.

  58. Wise PM, Smith MJ, Dubal DB. Neuroendocrine influences and repercussions of the menopause. Endoc Rev 1999; 20: 243-8.

  59. Velasco E, Malacara JM, Cervantes F, Díaz de León J, Dávalos G, Castillo J. Gonadotropins and prolactin serum levels during the perimenopausal period: Correlation with diverse factors. Fertil Steril 1990; 53: 56-60.

  60. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal Transition: a cross-sectional study of a population-based sample. J Clin Endoc Metab 1995; 80: 3537-45.

  61. Labrie F, Luu.The V, Labrie C. Endocrine and Intracrine Sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepinandroesterone. Endoc Rev 2003; 24: 152-182.

  62. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14: 245-255.

  63. van Zonneveld P, Scheffer GJ. Hormones and reproductive ageing. Maturitas 2001; 38: 83-94.

  64. Morato HL. Cambios endocrinos en la perimenopausia y la postmenopausia. En: S. Carranza-Lira: Atención Integral del Climaterio. Ed. Masson-Doyma, México, 2002: 25-37.

  65. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14: 245-255.

  66. Buckler HM, Evans CA, Mamtora H. Gonadotropin, steroid, and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory rebound cycles. J Clin Endocrinol Metab 1991; 72: 116-24.

  67. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate JH, exhaustion. J Clin Endocrinol Metab 1987; 65: 1231-6.

  68. Huerta R, Malacara JM, Fajardo ME, Nava LE, Bocanegra A, Sánchez J. High frequency FSH and LH pulses in obese menopausal women. Endocrine 1997; 7: 281-286.

  69. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol and progesterone concentrations during the menstrual cycle of older women. J Clin Endoc Metab 1976; 42: 629-36.

  70. Burger HG, Dudley EC, Hopper JL. Prospectively measured levels of serum follicle-stimulating hormone, estradiol and the dimeric inhibins during the menopausal transition in population-based cohort of women. J Clin Endoc Metab 1999; 84: 4025- 30.

  71. Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998; 19: 397-428.

  72. Santoro N, Brown JR, Adel T. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81: 1495- 501.

  73. Bancroft J, Cawood EH. Androgens and the menopause: a study of 40-60 year old women. Clin Endoc (Oxf) 1996; 45: 577-87.

  74. Arlt W, Justl HG, Callies F. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998; 83: 1928-1934.

  75. Labrie F, Luu-The V, Labrie C. Endocrine and Intracrine Sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandroesterone. Endocr Rev 2003; 24: 152-182.

  76. Arlt W. Androgen Therapy in women. Eur J Endocrinol 2006; 154: 1-11.

  77. Arlt W, Callies F, van Vlijmen JC. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013-1020.

  78. Kawano H, Yasue H, Kitagawa A. Dehydroepiandrosterone supplementation improves endotelial function and insulin sensitivity in men. J Clin Endoc Metab 2003; 88: 3190-3195.

  79. Kimonides VG, Khatibi NH, Svendsen CN. Dehydroepiandrosterone (DHEA) and DHEA-S protect Hyppocampal neurons against excitatory amino-acid induced neurotoxicity. Proc Natl Acad Sci 1998; 85: 1842-1867.

  80. Lovas K, Gebre-Medhin G, Trovik TS. Effect of DHEA on abdominal fat and insulin action in eldery women and men. A randomized study Controlled trial. JAMA 2004; 292: 2243-2248.

  81. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-376.

  82. Bachmann G, Bancroft J, Braunstein G. Female androgen insufficiency: The Princeton Consensus Statement on definition, classification and assessment. Fertil Steril 2002: 77: 660-665.

  83. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-29.

  84. Judd HL, Lucas WE, Judd GE. Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39: 1020-1024.

  85. Urban RJ. Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 1992; 21: 921-31.

  86. Katznelson L, Riskind PN, Saxe VC. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrin Metab 1998; 83: 761-764.

  87. Valles V. Factores de Riesgo cardiovascular en mujeres postmenopáusicas. Encuesta Nacional de Enfermedades Crónicas. Rev Inst Nal Nutr Salvador Zubirán 1994; 5: 20.

  88. Lozano-Ascencio R, Escamilla JA, Escobedo de la Peña J, López-Cervantes M. Tendencia de la mortalidad por cardiopatía isquémica en México, de 1950 a 1985. Salud Pública Mex 1990; 32: 406.

  89. Carr MC. The Emergence of the Metabolic Syndrome with Menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.

  90. Lerman GI, Aguilar-Salinas CA, Gómez-Pérez FJ. El síndrome metabólico. Posición de la Sociedad Mexicana de Nutrición y Endocrinología, sobre la definicion, fisiopatología y diagnóstico. Características del síndrome Metabólico en México. Rev Endoc Nutr 2004; 12: 109-122.

  91. Posadas RC, Yamamoto KL, Tapia CR. Epidemiología de las dislipidemias en México. En: C. Posadas R: Dislipidemias y Aterosclerosis, Edit. Interamericana, 1995: 117.

  92. Valles V. Factores de riesgo cardiovascular en mujeres postmenopáusicas. Encuesta Nacional de Enfermedades Crónicas. Rev Inst Nal Nutr Salvador Zubirán 1994; 5: 20.

  93. Morato HL, Lerman GI. Dislipidemias en el climaterio femenino y en ancianos. En: C. Posadas R. Dislipidemias y Aterosclerosis. Ed. Interamericana, 1995: 159-170.

  94. Morato HL. Dislipidemias. Alteraciones de la coagulación. En: JM Septién G. Climaterio: Estudio, diagnóstico y tratamiento. Edit. Intersistemas México, pp.: 106-112.

  95. Posadas CR, Brito ZO. Alteraciones metabólicas en el climaterio. En: S. Carranza-Lira: Atención Integral del Climaterio, Ed. Masson Doyma México, 2002: 101-115.

  96. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endoc Metab 1991; 73: 925-31.

  97. La Rosa JC. Metabolic effects of estrogens and progestins. Fert Ster 1994; 62 (suppl 2): S140.

  98. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) Trial. JAMA 1995; 273: 199-204.

  99. Mosca L. Estrógenos y aterosclerosis. Aterosclerosis 1999; 2(1).

  100. Grobbee DE. LIFT study to continue as planned. BMJ 2005; 331: 843.

  101. Saitta A, Altavilla D, Cucinotta D. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on NO concentrations, enothelin 1 levels and endothelium dependent vasodilation in postmenopausal women. Arterioescl Throm Vasc Biol 2001; 21: 1512-5.

  102. Lip GYH, Blann AD, Jones AF. Effects of HRT on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause. Am H J 1997; 134: 764.

  103. Tonstad S, Ose L, Gorberts C. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women. J Int Med 1995; 238: 39.

  104. Kats RJ, Hsia J, Walker P. Effects of hormonal replacement therapy on the circadian pattern of atherotrombotic risk factors. Am J Cardiol 1996; 78: 876.

  105. Hernández JS, Rodríguez CS, Pérez E. Tratamiento de las alteraciones metabólicas durante el climaterio. En: S. Carranza-Lira: Atención Integral del Climaterio. Ed. Masson- Doyma, México, 2002: 223-247.

  106. Gaspard UJ, Gottal JM, van den Brele FA. Postmenopausal changes of lipid and glucose metabolism; a review of their main aspects. Maturitas 1995; 21: 171-178.

  107. Hernández-Ono A, Monter-Carreola G, Zamora González J. Association of visceral fat with coronary risk factors in a population-based sample of postmenopausal women. Int J Obes 2002; 26: 33-9.

  108. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  109. Arriero PJ, Goran MI, Poehlman ET. Resting metabolic rate is lower in females compared to males. J Appl Physiol 1993; 75: 2514-2520.

  110. Guo SS, Zeller C, Cameron CW. Aging, body composition and lifestyle: The Fels Longitudinal Study. Am J Clin Nutr 1999; 70: 405-411.

  111. Crawford SL, Casey VA, Avis NE. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women´s Health Study. Menopause 2000; 7: 96-104.

  112. Crawford SL, Casey VA, Avis NE. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women´s Health Study. Menopause 2000; 7: 96-104.




2020     |     www.medigraphic.com